Sequence of interventions to prevent and successfully treat COVID-19 infection in patients with B-cell malignancies. Vaccinations are able to elicit seroconversion in up to two-thirds of patients with B-cell malignancies.⁶ Tixagevimab and cilgavimab reduced the probability of developing a symptomatic infection before the BA.4 BA.5 Omicron variants became predominant,⁴ and early administration of antiviral agents within 3 to 7 days from the onset of symptoms offered an effective protection against severe disease in the majority of patients.